Company: DMAC
Filing Date: 2025-08-01
Form Type: S-3
Source: 0001437749-25-024290
Chunk: 10

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-01
Form: S-3
Chunk 10
---
 Rights Agreement

Under the terms of the Securities Purchase Agreements, we entered into a registration rights agreement (Registration Rights Agreement) with the Purchasers pursuant to which we agreed to prepare and file a registration statement (Resale Registration Statement) with the SEC within 10 business days of the closing date for purposes of registering the resale of the common shares sold in the Private Placement. The registration statement of which this prospectus is a part has been filed to satisfy this obligation. Under the terms of the Registration Rights Agreement, we agreed to use our reasonable best efforts to cause the Resale Registration Statement to be declared effective by the SEC within 30 calendar days of the closing of the Private Placement (75 calendar days in the event the Resale Registration Statement is reviewed by the SEC). If we fail to meet the specified filing deadlines or keep the Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the selling shareholders. We also agreed, among other things, to indemnify the selling holder under the Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.

<div align='center'>4

The Offering</div>

| Common shares to be offered by the selling shareholders: |     | Up to 8,606,425 shares                                                                                                                                                                                                                                                    |
| Common shares to be outstanding after the offering:      |     | 51,688,913 shares                                                                                                                                                                                                                                                         |
| Use of proceeds:                                         |     | We will not receive any proceeds from the sale of shares in this offering. See “Use of Proceeds” beginning on page 10 of this prospectus.                                                                                                                                 |
| Risk factors:                                            |     | You should read the “Risk Factors” beginning on page 6 of this prospectus and the “Risk Factors” sections of the documents incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our common shares. |
| Stock exchange listing:                                  |     | Our common shares are listed on The Nasdaq Capital Market under the symbol “DMAC.”                                                                                                                                                                                        |

The number of our common shares to be outstanding after this offering is based on 51,688,913 common shares outstanding as of July 23, 2025, and excludes as of that date the following:

| ● | 5,711,194 common shares reserved for issuance upon the exercise of outstanding stock options under the DiaMedica Therapeutics Inc. Amended and Restated